Avid Bioservices Inc (CDMO)

[biopharm]

Thanks CJ! and nice to see that the foundation has already been built/building that stresses the MOA of Bavituximab as independent vs PD-1..

--------

Peregrine Pharmaceuticals' (PPHM) CEO Steve King on Q3 2015 Results - Earnings Call Transcript
...
...
..

Building on our strategy to disseminate our findings within the scientific and clinical medical communities, we recently presented data at the 2014 San Antonio Breast Cancer Symposium showing that the single-agent pre-clinical equivalent to bavituximab demonstrated statistically significant tumor growth inhibition as well as statistically significant increases in the percentages of CD4 and CD8 tumor infiltrating lymphocytes and decreases in tumor associated myeloid-derived suppressor cells, all of which are key indicators of immune activation in breast tumor models when compared to a control antibody.

These data confirms that the mechanism of action of bavituximab functions independent of PD-1 checkpoint blockade therefore further highlighting our opportunity for additive or synergistic effects with IO combination therapy.
...
...

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=111699449&txt2find=San|Antonio|Breast|Cancer|Symposium

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=111728918&txt2find=San|Antonio|Breast|Cancer|Symposium

----------